PT  - JOURNAL ARTICLE
AU  - Emily Mantlo
AU  - Natalya Bukreyeva
AU  - Junki Maruyama
AU  - Slobodan Paessler
AU  - Cheng Huang
TI  - Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection
AID  - 10.1101/2020.04.02.022764
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.04.02.022764
4099  - http://biorxiv.org/content/early/2020/04/05/2020.04.02.022764.1.short
4100  - http://biorxiv.org/content/early/2020/04/05/2020.04.02.022764.1.full
AB  - The ongoing historic outbreak of COVID-19 not only constitutes a global public health crisis, but also carries a devastating social and economic impact. The disease is caused by a newly identified coronavirus, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the remarkable sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α at a concentration of 50 international units (IU) per milliliter drastically reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potent efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.